Does the media favor DRTS or PROF?

In the previous week, Alpha Tau Medical had 6 more articles in the media than Profound Medical. MarketBeat recorded 9 mentions for Alpha Tau Medical and 3 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.88 beat Alpha Tau Medical's score of 0.18 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Tau Medical 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, INMD or PROF?

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.27 $93.83M $1.36 10.75 Profound Medical $16.10M 14.67 -$42.57M -$1.24 N/A

Is INMD or PROF more profitable?

InMode has a net margin of 23.27% compared to Profound Medical's net margin of -206.76%. InMode's return on equity of 13.47% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets InMode 23.27% 13.47% 11.95% Profound Medical -206.76% -78.88% -64.06%

Does the media favor INMD or PROF?

In the previous week, InMode had 5 more articles in the media than Profound Medical. MarketBeat recorded 8 mentions for InMode and 3 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.88 beat InMode's score of 0.59 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, BVS or PROF?

Bioventus has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $576.30M 1.42 $22.73M $0.41 23.85 Profound Medical $16.10M 14.67 -$42.57M -$1.24 N/A

Does the media favor BVS or PROF?

In the previous week, Profound Medical had 1 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for Profound Medical and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.96 beat Profound Medical's score of 0.88 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, SIBN or PROF?

SiBone has higher revenue and earnings than Profound Medical. SiBone is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.83 -$18.90M -$0.39 N/A Profound Medical $16.10M 14.67 -$42.57M -$1.24 N/A

Is SIBN or PROF more profitable?

SiBone has a net margin of -8.10% compared to Profound Medical's net margin of -206.76%. SiBone's return on equity of -9.56% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Profound Medical -206.76% -78.88% -64.06%

Does the media refer more to PROF or CBLL?

In the previous week, Profound Medical and Profound Medical both had 3 articles in the media. CeriBell's average media sentiment score of 1.64 beat Profound Medical's score of 0.88 indicating that CeriBell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profound Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CeriBell 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Profound Medical (PROF) Competitors

$6.50 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$6.72 +0.22 (+3.38%)

As of 07:11 AM Eastern

Compare

PROF vs. DRTS, INMD, BVS, SIBN, and CBLL

Should you buy Profound Medical stock or one of its competitors? MarketBeat compares Profound Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Profound Medical include Alpha Tau Medical (DRTS), InMode (INMD), Bioventus (BVS), SiBone (SIBN), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.

How does Profound Medical compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Profound Medical has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A
Profound Medical	$16.10M	14.67	-$42.57M	-$1.24	N/A

Alpha Tau Medical has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alpha Tau Medical has a net margin of 0.00% compared to Profound Medical's net margin of -206.76%. Alpha Tau Medical's return on equity of -73.23% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-73.23%	-52.90%
Profound Medical	-206.76%	-78.88%	-64.06%

In the previous week, Alpha Tau Medical had 6 more articles in the media than Profound Medical. MarketBeat recorded 9 mentions for Alpha Tau Medical and 3 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.88 beat Alpha Tau Medical's score of 0.18 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Tau Medical presently has a consensus price target of $12.60, suggesting a potential upside of 15.81%. Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 84.62%. Given Profound Medical's higher possible upside, analysts clearly believe Profound Medical is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Alpha Tau Medical beats Profound Medical on 9 of the 15 factors compared between the two stocks.

How does Profound Medical compare to InMode?

InMode (NASDAQ:INMD) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

InMode has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

68.0% of InMode shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

InMode presently has a consensus target price of $16.00, suggesting a potential upside of 9.39%. Profound Medical has a consensus target price of $12.00, suggesting a potential upside of 84.62%. Given Profound Medical's higher probable upside, analysts clearly believe Profound Medical is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMode has a net margin of 23.27% compared to Profound Medical's net margin of -206.76%. InMode's return on equity of 13.47% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Profound Medical	-206.76%	-78.88%	-64.06%

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.27	$93.83M	$1.36	10.75
Profound Medical	$16.10M	14.67	-$42.57M	-$1.24	N/A

In the previous week, InMode had 5 more articles in the media than Profound Medical. MarketBeat recorded 8 mentions for InMode and 3 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.88 beat InMode's score of 0.59 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InMode beats Profound Medical on 11 of the 14 factors compared between the two stocks.

How does Profound Medical compare to Bioventus?

Bioventus (NASDAQ:BVS) and Profound Medical (NASDAQ:PROF) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Bioventus has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$576.30M	1.42	$22.73M	$0.41	23.85
Profound Medical	$16.10M	14.67	-$42.57M	-$1.24	N/A

Bioventus currently has a consensus price target of $14.20, suggesting a potential upside of 45.19%. Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 84.62%. Given Profound Medical's higher probable upside, analysts plainly believe Profound Medical is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bioventus has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

62.9% of Bioventus shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bioventus has a net margin of 4.94% compared to Profound Medical's net margin of -206.76%. Bioventus' return on equity of 29.97% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Profound Medical	-206.76%	-78.88%	-64.06%

In the previous week, Profound Medical had 1 more articles in the media than Bioventus. MarketBeat recorded 3 mentions for Profound Medical and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.96 beat Profound Medical's score of 0.88 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bioventus beats Profound Medical on 13 of the 17 factors compared between the two stocks.

How does Profound Medical compare to SiBone?

SiBone (NASDAQ:SIBN) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

98.1% of SiBone shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 3.9% of SiBone shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SiBone presently has a consensus price target of $23.00, suggesting a potential upside of 32.72%. Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 84.62%. Given Profound Medical's higher possible upside, analysts plainly believe Profound Medical is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Profound Medical had 2 more articles in the media than SiBone. MarketBeat recorded 3 mentions for Profound Medical and 1 mentions for SiBone. SiBone's average media sentiment score of 1.87 beat Profound Medical's score of 0.88 indicating that SiBone is being referred to more favorably in the media.

Company	Overall Sentiment
SiBone	Very Positive
Profound Medical	Positive

SiBone has a net margin of -8.10% compared to Profound Medical's net margin of -206.76%. SiBone's return on equity of -9.56% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Profound Medical	-206.76%	-78.88%	-64.06%

SiBone has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

SiBone has higher revenue and earnings than Profound Medical. SiBone is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.83	-$18.90M	-$0.39	N/A
Profound Medical	$16.10M	14.67	-$42.57M	-$1.24	N/A

Summary

SiBone beats Profound Medical on 11 of the 16 factors compared between the two stocks.

How does Profound Medical compare to CeriBell?

Profound Medical (NASDAQ:PROF) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Profound Medical has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	14.67	-$42.57M	-$1.24	N/A
CeriBell	$95.07M	7.97	-$53.41M	-$1.63	N/A

Profound Medical currently has a consensus target price of $12.00, indicating a potential upside of 84.62%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 11.11%. Given Profound Medical's higher possible upside, equities analysts clearly believe Profound Medical is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Profound Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

In the previous week, Profound Medical and Profound Medical both had 3 articles in the media. CeriBell's average media sentiment score of 1.64 beat Profound Medical's score of 0.88 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CeriBell	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CeriBell has a net margin of -63.51% compared to Profound Medical's net margin of -206.76%. CeriBell's return on equity of -38.19% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
CeriBell	-63.51%	-38.19%	-30.92%

47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 20.1% of CeriBell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

CeriBell beats Profound Medical on 10 of the 16 factors compared between the two stocks.

Get Profound Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROF vs. The Competition

Export

Metric	Profound Medical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$236.21M	$3.02B	$6.83B	$12.17B
Dividend Yield	N/A	1.88%	2.67%	6.11%
P/E Ratio	-5.24	19.54	25.89	24.17
Price / Sales	14.67	330.34	545.01	100.37
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	3.55	4.21	10.75	6.38
Net Income	-$42.57M	$64.45M	$3.58B	$337.00M
7 Day Performance	-0.61%	1.32%	1.90%	-0.23%
1 Month Performance	-4.55%	-1.07%	-0.26%	-1.40%
1 Year Performance	8.33%	29.70%	34.39%	27.76%

Profound Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROF Profound Medical	1.8202 of 5 stars	$6.50 flat	$12.00 +84.6%	+8.3%	$236.21M	$16.10M	N/A	150	Analyst Upgrade Gap Down
DRTS Alpha Tau Medical	2.9628 of 5 stars	$9.80 -2.3%	$12.60 +28.6%	+265.1%	$885.23M	N/A	N/A	80	Insider Trade Gap Down
INMD InMode	1.5671 of 5 stars	$13.35 +1.1%	$16.00 +19.9%	+3.1%	$845.86M	$370.49M	9.82	480	Gap Up
BVS Bioventus	4.1791 of 5 stars	$9.29 +5.7%	$14.20 +52.9%	N/A	$776.04M	$576.30M	22.66	1,200
SIBN SiBone	2.4179 of 5 stars	$15.95 +0.8%	$23.00 +44.2%	-6.0%	$707.37M	$206.22M	N/A	350	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROF) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profound Medical (PROF) Competitors

PROF vs. DRTS, INMD, BVS, SIBN, and CBLL

How does Profound Medical compare to Alpha Tau Medical?

Summary

How does Profound Medical compare to InMode?

Summary

How does Profound Medical compare to Bioventus?

Summary

How does Profound Medical compare to SiBone?

Summary

How does Profound Medical compare to CeriBell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profound Medical (PROF) Competitors

PROF vs. DRTS, INMD, BVS, SIBN, and CBLL

How does Profound Medical compare to Alpha Tau Medical?

Which has higher earnings & valuation, DRTS or PROF?

Which has more risk & volatility, DRTS or PROF?

Do insiders & institutionals hold more shares of DRTS or PROF?

Is DRTS or PROF more profitable?

Does the media favor DRTS or PROF?

Do analysts rate DRTS or PROF?

Summary

How does Profound Medical compare to InMode?

Which has more volatility and risk, INMD or PROF?

Do insiders & institutionals have more ownership in INMD or PROF?

Do analysts recommend INMD or PROF?

Is INMD or PROF more profitable?

Which has higher valuation & earnings, INMD or PROF?

Does the media favor INMD or PROF?

Summary

How does Profound Medical compare to Bioventus?

Which has preferable earnings and valuation, BVS or PROF?

Do analysts recommend BVS or PROF?

Which has more volatility & risk, BVS or PROF?

Do institutionals and insiders have more ownership in BVS or PROF?

Is BVS or PROF more profitable?

Does the media favor BVS or PROF?

Summary

How does Profound Medical compare to SiBone?

Do institutionals and insiders have more ownership in SIBN or PROF?

Do analysts prefer SIBN or PROF?

Does the media favor SIBN or PROF?

Is SIBN or PROF more profitable?

Which has more volatility and risk, SIBN or PROF?

Which has better valuation & earnings, SIBN or PROF?

Summary

How does Profound Medical compare to CeriBell?

Which has preferable valuation and earnings, PROF or CBLL?

Do analysts recommend PROF or CBLL?

Which has more volatility and risk, PROF or CBLL?

Does the media refer more to PROF or CBLL?

Is PROF or CBLL more profitable?

Do institutionals & insiders believe in PROF or CBLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools